Carlisle Companies heads into its July 29 Q2 results with options traders notably more cautious than they were just a week ago — even as the short-selling retreat that defined the earlier preview continues.
The clearest shift since the July 21 preview is in options positioning. The put/call ratio has climbed to 0.91, well above its 20-day mean of 0.79 and roughly 1.2 standard deviations from that average. That marks a meaningful move: the PCR ran as low as 0.64 in early July and has been climbing steadily toward the print. Investors are buying more downside protection now than at any point in the past six weeks. The stock itself is down 5% over the past month to $336.04, and off a further 2.7% on the week — underperforming most building-products peers, which largely rose on Friday. UFPI, SSD, LPX, and BLDR all gained between 2% and 3.3% on Thursday, while CSL lagged.
Short interest, by contrast, tells a calmer story. The position now amounts to 5.1% of the free float — essentially unchanged from the July 21 article — and has actually eased 15% from a month ago. Borrow availability has loosened further to 579%, up from 559% a week ago, and the cost to borrow has ticked down to 0.49%. There is no squeeze tension in the lending market. The ORTEX short score has also continued its mild drift lower, from 47.5 at the prior preview to 47.1 now — a direction that says short sellers are not pressing new positions ahead of the release.
The fundamental debate is unchanged but unresolved. Bulls point to the CWT segment's acquisition-driven revenue momentum and the prospect of a recovery in non-residential construction lifting the larger CCM division. Bears focus on CCM's guidance for a low single-digit volume decline, the 8% year-over-year EBITDA contraction that accompanied the prior print, and competitive pricing pressure. Baird cut its target to $405 on July 20 while holding an Outperform — a signal that even constructive analysts are nudging down expectations ahead of the number. Truist, holding at Hold, already trimmed to $340 on July 7, bracketing the stock's current level with little implied upside. The consensus mean target of $403 still sits about 20% above the current price, but the direction of recent revisions is downward.
The July 29 print will test whether CCM's volume trends have stabilized enough to justify the gap between where the stock trades and where the Street still values it — or whether another quarter of margin pressure widens that divide further.
See the live data behind this article on ORTEX.
Open CSL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
